Search results
Lack of insurance keeps many Americans from best cancer meds
Medical Xpress· 3 days agoThe study was led by ACS researcher Dr. Jingxuan Zhao. ICIs include such blockbuster cancer...
CG Oncology reports promising bladder cancer trial results By Investing.com
Investing.com· 6 hours agoThe study, focusing on patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC),...
Neoadjuvant Strategy Establishes Standard of Care for Resectable Stage III Melanoma
MedPage Today· 3 days agoCombination neoadjuvant immunotherapy for resectable melanoma reduced recurrence and other clinical...
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of...
Morningstar· 3 days agoTAMPA, FL and SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome ...
Newswise Expert | Toni Choueiri, Dana-Farber Cancer Institute
Newswise· 2 days agoDr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney
Lack of insurance may prevent Americans from accessing best cancer drugs
UPI· 3 days agoA cutting-edge class of drugs is saving and extending the lives of cancer patients. But the drugs,...
From immunotherapy to mRNA vaccines – the latest science on melanoma treatment explained
The Conversation· 2 days agoMore than 16,000 Australians will be diagnosed with melanoma each year. Over the past decade, these treatments have seen a significant climb in the number of advanced melanoma patients surviving ...
Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents
MedPage Today· 6 days agoChina-based trial may present a hurdle to FDA approval, however
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With...
Benzinga· 4 days agoData show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; "ITT") who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line